1. Market Research
  2. > Spinal Cord Disorders – Pipeline Review, H1 2013

Spinal Cord Disorders – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 151 pages

Spinal Cord Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Spinal Cord Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Spinal Cord Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Cord Disorders. Spinal Cord Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Spinal Cord Disorders.
- A review of the Spinal Cord Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Spinal Cord Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Spinal Cord Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Spinal Cord Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Spinal Cord Disorders - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Spinal Cord Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Spinal Cord Disorders 9
Spinal Cord Disorders Therapeutics under Development by Companies 11
Spinal Cord Disorders Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Spinal Cord Disorders Therapeutics - Products under Development by Companies 21
Spinal Cord Disorders Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Spinal Cord Disorders Therapeutics Development 25
F. Hoffmann-La Roche Ltd. 25
Scil Technology Gmbh 26
Novartis AG 27
Isotechnika Pharma Inc. 28
Daewoong Pharmaceutical Co., Ltd. 29
Pfizer Inc. 30
Teva Pharmaceutical Industries Limited 31
Paratek Pharmaceuticals, Inc. 32
Oxygen Biotherapeutics, Inc. 33
Proneuron Biotechnologies, Inc. 34
Neuralstem, Inc. 35
Kaken Pharmaceutical Co.,Ltd. 36
Mesoblast Ltd 37
KOLON LIFE SCIENCE INC. 38
LTT Bio-Pharma Co., Ltd. 39
Sucampo Pharmaceuticals, Inc. 40
Asubio Pharmaceuticals, Inc. 41
Trophos SA 42
Q Therapeutics, Inc. 43
Asahi Kasei Pharma 44
NEURONAX 45
TissueGene, Inc. 46
Omeros Corporation 47
Nexgenix Pharmaceuticals, LLC 48
Genethon 49
California Stem Cell, Inc. 50
Spinal Cord Disorders - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 58
BA-210 - Drug Profile 58
DWP-431 - Drug Profile 61
LT-0101 - Drug Profile 62
SPI-017 - Drug Profile 63
ecraprost - Drug Profile 64
RG-3039 - Drug Profile 66
Oxycyte - Drug Profile 68
beraprost sodium SR - Drug Profile 70
olesoxime - Drug Profile 71
PTK-SMA-2 - Drug Profile 74
NXD-30001 - Drug Profile 76
PN-277 - Drug Profile 77
Recombinant Human Growth And Differentiation Factor-5 - Drug Profile 78
ATI-355 - Drug Profile 79
dichlorphenamide - Drug Profile 80
Humanized Mik-(Beta)-1 - Drug Profile 81
Q-Cells - Drug Profile 82
SPI-3608 - Drug Profile 83
KUR-115 - Drug Profile 84
MotorGraft - Drug Profile 85
NSI-566RSC - Drug Profile 86
NeoFuse - Drug Profile 88
CNV-1014802 - Drug Profile 90
pentoxifylline - Drug Profile 92
GPR161 Antagonist - Drug Profile 93
ATNC-05 - Drug Profile 94
Drug For Spinal Muscular Atrophy - Drug Profile 95
SUN-13837 - Drug Profile 96
Drug Program For Spinal Muscular Atrophy - Drug Profile 97
SMN-2 - Drug Profile 98
lithium carbonate + Umbilical Cord Blood Mononuclear Cell Transplant - Drug Profile 99
RE-003 - Drug Profile 101
Cs - Drug Profile 102
fasudil - Drug Profile 103
TG-D - Drug Profile 104
Drug for Spinal Muscular Atrophy - Drug Profile 105
ST-01 - Drug Profile 106
elcatonin - Drug Profile 107
ND-602 - Drug Profile 108
Autologous Schwann Cells - Drug Profile 109
Autologous Schwann Cells - Drug Profile 111
valproate sodium + [levocarnitine] - Drug Profile 113
NuQu Cell-Based Therapy - Drug Profile 114
CEP-4143 - Drug Profile 115
Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 116
NICAM Program - Drug Profile 117
AAV9-SMN Gene Therapy Program - Drug Profile 119
NX-210 - Drug Profile 120
Motor Neuron Precursor Cells - Drug Profile 121
Spinal Muscular Atrophy Program - Drug Profile 122
Injectable Discosphere Cell Therapy (IDCT) - Drug Profile 123
Spinal Cord Disorders Therapeutics - Drug Profile Updates 124
Spinal Cord Disorders Therapeutics - Discontinued Products 136
Spinal Cord Disorders Therapeutics - Dormant Products 137
Spinal Cord Disorders - Product Development Milestones 139
Featured News and Press Releases 139
Appendix 147
Methodology 147
Coverage 147
Secondary Research 147
Primary Research 147
Expert Panel Validation 147
Contact Us 148
Disclaimer 148



List of Tables

Number of Products Under Development for Spinal Cord Disorders, H1 2013 12
Products under Development for Spinal Cord Disorders - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Comparative Analysis by Late Stage Development, H1 2013 20
Comparative Analysis by Mid Clinical Stage Development, H1 2013 21
Comparative Analysis by Early Clinical Stage Development, H1 2013 22
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Development by Companies, H1 2013 (Contd..1) 25
Products under Development by Companies, H1 2013 (Contd..2) 26
Products under Investigation by Universities/Institutes, H1 2013 27
F. Hoffmann-La Roche Ltd., H1 2013 28
Scil Technology Gmbh, H1 2013 29
Novartis AG, H1 2013 30
Isotechnika Pharma Inc., H1 2013 31
Daewoong Pharmaceutical Co., Ltd., H1 2013 32
Pfizer Inc., H1 2013 33
Teva Pharmaceutical Industries Limited, H1 2013 34
Paratek Pharmaceuticals, Inc., H1 2013 35
Oxygen Biotherapeutics, Inc., H1 2013 36
Proneuron Biotechnologies, Inc., H1 2013 37
Neuralstem, Inc., H1 2013 38
Kaken Pharmaceutical Co.,Ltd., H1 2013 39
Mesoblast Ltd, H1 2013 40
KOLON LIFE SCIENCE INC., H1 2013 41
LTT Bio-Pharma Co., Ltd., H1 2013 42
Sucampo Pharmaceuticals, Inc., H1 2013 43
Asubio Pharmaceuticals, Inc., H1 2013 44
Trophos SA, H1 2013 45
Q Therapeutics, Inc., H1 2013 46
Asahi Kasei Pharma, H1 2013 47
NEURONAX, H1 2013 48
TissueGene, Inc., H1 2013 49
Omeros Corporation, H1 2013 50
Nexgenix Pharmaceuticals, LLC, H1 2013 51
Genethon, H1 2013 52
California Stem Cell, Inc., H1 2013 53
Assessment by Monotherapy Products, H1 2013 54
Assessment by Combination Products, H1 2013 55
Assessment by Stage and Route of Administration, H1 2013 57
Assessment by Stage and Molecule Type, H1 2013 60
Spinal Cord Disorders Therapeutics - Drug Profile Updates 127
Spinal Cord Disorders Therapeutics - Discontinued Products 139
Spinal Cord Disorders Therapeutics - Dormant Products 140
Spinal Cord Disorders Therapeutics - Dormant Products (Contd..1) 141



List of Figures

Number of Products under Development for Spinal Cord Disorders, H1 2013 12
Products under Development for Spinal Cord Disorders - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 20
Mid Clinical Stage Products, H1 2013 21
Early Clinical Stage Products, H1 2013 22
Discovery and Pre-Clinical Stage Products, H1 2013 23
Assessment by Monotherapy Products, H1 2013 54
Assessment by Combination Products, H1 2013 55
Assessment by Route of Administration, H1 2013 56
Assessment by Stage and Route of Administration, H1 2013 57
Assessment by Molecule Type, H1 2013 58
Assessment by Stage and Molecule Type, H1 2013 59

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.